{"id":"enalapril-maleate-and-folic-acid-tablets","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Dry cough"},{"rate":"5-10","effect":"Dizziness"},{"rate":"3-5","effect":"Fatigue"},{"rate":"2-5","effect":"Hyperkalemia"},{"rate":"<1","effect":"Angioedema"},{"rate":"2-5","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL1200659","moleculeType":"Small molecule","molecularWeight":"492.53"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Enalapril maleate is an ACE inhibitor that blocks the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion, thereby lowering blood pressure and reducing cardiac workload. Folic acid (vitamin B9) is included as a supplementary component to support methylation reactions and reduce homocysteine levels, which may provide additional cardiovascular benefit in hypertensive patients.","oneSentence":"Enalapril inhibits angiotensin-converting enzyme (ACE) to reduce blood pressure, while folic acid supplementation supports cellular methylation and DNA synthesis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:42:18.265Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Heart failure"},{"name":"Post-myocardial infarction cardioprotection"}]},"trialDetails":[{"nctId":"NCT02575092","phase":"PHASE2, PHASE3","title":"The Relationship Between HHcy and Contrast-induced Nephropathy in Hypertensive Patients After Coronary Artery Diagnosis and Treatment","status":"COMPLETED","sponsor":"Fuling Central Hospital of Chongqing City","startDate":"2015-11-01","conditions":"Homocysteine, Coronary Disease, Angioplasty,Balloon,Coronary","enrollment":4000},{"nctId":"NCT03472508","phase":"PHASE4","title":"H-Type Hypertension Precision Medicine Trial","status":"UNKNOWN","sponsor":"Shenzhen Ausa Pharmed Co.,Ltd","startDate":"2018-03-20","conditions":"Hypertension","enrollment":3600},{"nctId":"NCT01871740","phase":"PHASE4","title":"CSPPT- Chronic Kidney Diseases Study","status":"WITHDRAWN","sponsor":"Shenzhen Ausa Pharmed Co.,Ltd","startDate":"2008-05","conditions":"Hypertension, Hyperhomocysteinemia","enrollment":""},{"nctId":"NCT00794885","phase":"PHASE4","title":"China Stroke Primary Prevention Trial","status":"COMPLETED","sponsor":"Shenzhen Ausa Pharmed Co.,Ltd","startDate":"2008-05","conditions":"Primary Hypertension","enrollment":20702}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"RENAL INJURY"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Enalapril maleate and folic acid tablets","genericName":"Enalapril maleate and folic acid tablets","companyName":"Shenzhen Ausa Pharmed Co.,Ltd","companyId":"shenzhen-ausa-pharmed-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Enalapril inhibits angiotensin-converting enzyme (ACE) to reduce blood pressure, while folic acid supplementation supports cellular methylation and DNA synthesis. Used for Hypertension, Heart failure, Post-myocardial infarction cardioprotection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}